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ABSTRACT 
 
Background/Objectives: Attention Deficit Hyperactivity Disorder (ADHD), one of the 
most common neurodevelopmental disorders in childhood and adolescence, is 
associated with obesity in observational studies. However, it is unclear whether ADHD 
contributes to, results from or is merely correlated with obesity. This study evaluates the 
presence and direction of a causal effect between ADHD and obesity. 
Subjects/Methods: We performed a bidirectional two-sample Mendelian 
randomization using summary data from consortia of genome-wide association studies 
to investigate if ADHD (N=55 374) has a causal effect on body mass index (BMI) in 
childhood (N= 35 668) and adulhood  (N=322 154 to 500 000), and vice-versa. The 
main analysis was performed using the Inverse Variance Weighted (IVW) method. As 
sensitivity analyses, we used other Mendelian randomization methods that are more 
robust to horizontal pleiotropy (i.e. MR-Egger, weighted mode and penalized weighted 
median estimators), as well as stratified the analysis by the putative mechanisms of 
genetic instruments (i.e. pathways involved or not in neurological processes). Results: 
The IVW method indicated a positive causal effect of BMI on ADHD: β=0.324 (95%CI 
0.198 to 0.449, p<0.001; expressed as change in ln(odds ratio) of ADHD per each 
additional SD unit of BMI). IVW estimates were directionally consistent with other 
methods. On the other hand, we did not find consistent evidence for a causal effect of 
ADHD genetic liability on BMI. Conclusions: The results suggested that higher BMI 
increases the risk of developing ADHD, but not the other way around.  
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INTRODUCTION 
 
Obesity and Attention Deficit Hyperactivity Disorder (ADHD) are common 
clinical conditions. Obesity has become a worldwide epidemic 1, implicated in the 
etiology of cardiovascular and metabolic diseases 2. ADHD may increase the risk of 
important conditions, including professional and educational disadvantages 3, substance 
use disorders 4, and involvement in criminal offenses 5, car accidents 6 and injuries 7. 
Studies in diverse settings have reported an association between ADHD and obesity 8-11. 
A recent meta-analysis including 42 studies worldwide and a total of 728 126 
participants (48 161 ADHD cases) estimated a pooled odds ratio for obesity of 1.3 
(95%CI: 1.16 to 1.46) in children/adolescents and adults with ADHD compared to non-
affected individuals 12. There is also robust evidence of a positive genetic correlation 
between ADHD and BMI from different approaches, such as LD score regression 13, 
genetic markers for BMI 14 and polygenic risk scores for ADHD risk 15. 
Despite the well-established phenotypic and genetic correlation between 
ADHD risk and BMI, the causal relationship between these two traits remain 
unknown. It has been hypothesized that ADHD may contribute to obesity due to 
impulsivity and inattention symptoms, which could lead to over-consumption or 
difficulties to follow a regular eating pattern 12, 16-18. Alternatively, ADHD might be a 
consequence of obesity19, 20. Few studies have explored this possibility and mechanisms 
are not clear, although obesity-induced sleeping problems, inflammation, and chronic 
hyperglycemia have been hypothesized as potential mechanisms 19, 21, 22. It is also 
possible that the association between ADHD and obesity may arise due to non-causal 
mechanisms, such as confounding, where a common factor may contribute to the 
development of both conditions 22.  
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Due to the observational nature of most studies on the association between 
ADHD and obesity, the current evidence on this topic may be distorted due to biases 
such as residual confounding. Therefore it is important to re-assess this association 
using different approaches that are more robust to this type of bias under a triangulation 
perspective 23. One of such methods is Mendelian randomization is a method that uses 
genetic variants associated with modifiable exposures as instrumental variables (IVs), 
aiming to assess causality between the exposures and the outcomes. Valid causal 
inference using Mendelian randomization requires that (i) relevance: the IV is strongly 
associated with the exposure of interest; (ii) independence: the IV is independent of the 
confounding factors between outcome and exposure; and (iii) exclusion restriction: the 
effect of IV on outcome is fully mediated by the exposure 24. 
A previous Mendelian randomization study has assessed the effect of BMI on 
several psychiatric disorders, which was not supportive of the notion that higher BMI 
increases the risk of developing bipolar disorder and schizophrenia, although there was 
a suggestive causal effect on major depression 25. To the best of our knowledge, no 
previous Mendelian randomization study has investigated the relationship between 
ADHD and BMI. In this study, we used Mendelian randomization to assess the presence 
and direction of a causal effect between obesity and ADHD.  
  
METHODS 
 
Study design 
 
We performed a bidirectional two-sample Mendelian randomization analysis 
using summary data from genome-wide association studies (GWAS) consortia to 
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investigate whether obesity is a cause or a consequence of ADHD, or if these two traits 
are correlated due to factors other than a causal relationship between obesity and ADHD 
(e.g. confounding). Genetic variants identified from the ADHD GWAS were looked up 
in the BMI GWAS to estimate the causal effect of ADHD on obesity and associations 
were also ascertained in the opposite direction.  
 
Data sources 
 
Data on the association between genetic polymorphisms and the phenotypes of 
interest was extracted from publicly available datasets of summary association results 
from four GWAS consortia.  
 
The Psychiatric Genomics Consortium (PGC) 
 
Summary association results for ADHD were extracted from a GWAS 
conducted by the PGC 13. The study was composed of 20 183 ADHD cases and 35 191 
controls, including children and adults iPSYCH study, and 11 European, North 
American and Chinese studies 13. Both family and case-control studies were included. 
European ancestry individuals comprised 96.25% of the sample. The genome-wide 
association analysis was conducted in each cohort using logistic regression, assuming 
additive genetics effects. Ancestry-informative principal components calculated using 
genome-wide genotyping data were included as covariates to minimize bias due to 
population stratification, along with relevant study-specific covariates where applicable. 
Variants with imputation quality score (INFO) <0.8 or minor allele frequency (MAF) 
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<0.01 were excluded. Twelve independent (r2< 0.1) genetic variants strongly associated 
with ADHD (P<5×10-8) were identified. Further details can be found elsewhere 13.  
 
The Early Growth Genetics (EGG) consortium 
 
The EGG discovery phase consisted of 20 studies including 35 668 children of 
European ancestry (from 2 to 10 years of age). Syndromic cases of obesity were 
excluded. Sex- and age-adjusted standard deviation scores were created for BMI at the 
latest time point available (oldest age) for each cohort if multiple measurements existed. 
The association estimates were obtained through linear regression, assuming an additive 
genetic model. The data used here includes the results from the discovery phase. 
In total, 18 loci reached genome-wide significance (P<5×10-8) in the EGG joint 
discovery and replication analyses. More details can be obtained in 26. We estimate that 
up to 4.2% of PGC participants might have been included in EGG consortium 
(Supplementary Table 2).  
For replication purposes we have used two other largely independent summary 
association results for BMI in adults, described below. 
 
The Genetic Investigation of Anthropometric Traits (GIANT) 
 
Summary association results for BMI were extracted from the GIANT 
consortium 27. The pooled sample included 322 154 and 17 072 adults of European and 
non-European ancestry, respectively, from GWAS and Metabochip studies. Here, we 
considered the 77 independent (500 kilo-bases apart) genetic variants that reached 
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genome-wide significance in the sex-combined analysis exclusively for individuals of 
European ancestry sample 27.  
 
The UK Biobank 
 
UK Biobank is a national prospective cohort that recruited more than 500 000 
men and women from across the United Kingdom, with aged 40 to 69 years between 
2006 to 2010. The association analysis with BMI was performed using 10.8 million 
Single Nucleotide Polymorphisms (SNPs), assuming additive genetic effects and 
excluding variants with MAF<0.01 and INFO<0.8. For this study, we used publicly 
available summary association results for BMI 28. Details on sample and SNP quality 
control can be found in UK Biobank documentation 29, 30. 
 
Genetic Instruments  
 
As genetic instruments for ADHD or BMI, we selected independent (as defined 
by each study) genetic instruments strongly associated (P<5×10-8) with ADHD and 
BMI, respectively, as described above. When the selected (index) genetic instrument 
was not available in the outcome GWAS, we replaced it by a proxy variant (R2>0.80) 
when possible, using the European population from 1000 genomes (phase 3 version 5) 
31 as reference pannel. Proxies of ADHD instruments were identified using the SNP 
Annotator (SNiPA) v3.2 and LDlink tools 32, 33. For proxies of BMI instruments, we 
used the R package Two-sample MR 34. 
From the 12 genetic instruments selected as instruments for ADHD, we were 
able to find nine (four index and five proxies) in EGG, ten (six index and four proxy) in 
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GIANT, and nine (seven index and two proxy) in UK Biobank datasets of summary 
GWAS results (Supplementary Table 1). 
From the 18 polymorphisms selected as instruments for BMI in childhood from 
EGG, 16 were identified in the ADHD dataset of summary GWAS results. From the 77 
genetic instruments selected as BMI instruments in adulthood from GIANT 27, 72 were 
found in the ADHD dataset. No other large ADHD GWAS was available to for 
replication. 
 
Mendelian randomization analysis 
 
We estimated the effect of BMI on ADHD (and vice-versa) using the Inverse 
Weighted Variance (IVW) estimator, which consists of a linear regression of the 
instrument-outcome association estimates on the instrument-exposure association 
estimates, weighted by the inverse of the variance of the instrument-outcome 
association estimates. The intercept of this regression is constrained at zero, which 
corresponds to the assumption that the genetic instruments can only affect the outcome 
through the exposure or that horizontal pleiotropic effects are balanced 35.   
 
Sensitivity analyses 
 
To assess the robustness of the primary analysis, we used other Mendelian 
randomization estimators that are more robust to horizontal pleiotropy than the IVW 
estimator: MR-Egger regression, Penalized Weighted Median (PMW) and the weighted 
mode-based estimator (MBE). 
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The MR-Egger regression consistently estimates the causal effect even if all 
genetic instruments violate the exclusion restriction assumption, as long as the 
Instrument Strength Independent of Direct Effect (InSIDE) assumption holds. InSIDE 
requires that the strength of the instrument (i.e., the association between the instrument 
and the exposure) is not correlated with the direct effect of the instrument on the 
outcome (i.e., the effect of the instrument on the outcome via horizontal pleiotropy) 36. 
The PMW method gives consistent estimates even if up to (but not including) half of the 
weight in the analysis comes from valid instruments, where each instrument that 
contributes to high heterogeneity (i.e., that yields a causal effect estimate substantially 
different than the most of the remaining instruments) is downweighted (penalized) 37. 
The weighted MBE requires the ZEro Modal Pleiotropy Assumption (ZEMPA) holds. 
ZEMPA postulates that the most common (i.e., the mode) horizontal pleiotropic effect 
is zero, which allows consistent causal effect estimation even if most instruments are 
invalid. The weighted version of ZEMPA can be interpreted as postulating that the 
homogeneous subset of instruments with the largest sum of weights comprises only 
valid instruments 38. 
Additional sensitivity analyses were performed by stratifying the BMI genetic 
instruments from GIANT according to the functional class of the protein encoded by the 
mapped gene, as identified by Locke et al., (2015) 27. More specifically, the instruments 
were classified into two classes: instruments likely to directly regulate 
neurophysiological processes versus other instruments. The neural pathways included 
the categories labelled in the original publication as Neuronal Developmental processes, 
Neurotransmission, Neuronal Expression and Hypothalamic expression and regulatory 
function. The other pathways included those not described as a neuro-related process, 
such as lipid biosynthesis and metabolism, bone development, mitochondrial, 
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endocytosis/exocytosis, tumorigenesis, immune system and limb development. The 
genetic instruments used in each dataset are fully described in the supplementary table 
3. Similar methodology was already used to estimate the causal effect of BMI in other 
psychiatric disorders 25.  
We have also performed a leave-one-out analysis to identify potentially overly 
influential instruments by removing 1 variant at a time and recalculating the IVW 
estimate. 
The analyses were performed using the R (https://www.r-project.org/) package 
Two-sample MR package 39. 
 
 
RESULTS 
 
Effect of ADHD susceptibility on BMI  
Results for the effect of ADHD susceptibility on BMI are expressed as change in 
BMI standard deviation (SD) units per each additional unit the ln(odds ratio) of ADHD, 
that is the natural logarithm of the odds ratio. The negative estimates indicate a negative 
(inverse) association; positive estimate indicates a positive association; a point estimate 
equal to zero indicates no association.  
Overall, the evidence ADHD genetic liability causally affects BMI was 
inconsistent across data sources and methods. In the main analyses (IVW), we found 
some evidence that higher ADHD liability increases BMI in EGG (β=0.095, 95% CI: 
0.011 to 0.179, p=0.025) and UK Biobank (β=0.074, 95% CI: 0.027 to 0.118, p=0.002), 
but not in GIANT (β=0.023, 95% CI: -0.018 to 0.065, p=0.280) (Figure 1a; Figure 1c; 
Figure 1b, Supplementary Table 4). In sensitivity analyses using methods that are more 
robust to pleiotropic instruments, we observed similar results for penalized weighted 
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median and weighted mode, but inconsistent results for MR-Egger (Supplementary 
Table 4). MR-Egger estimates were in the opposite direction to IVW estimates in UK 
Biobank (β= -0.059, 95% CI: -0.248 to 0.129, p=0.554) and GIANT (β= -0.065, 95% 
CI: -0.255 to 0.124, p=0.518) (Figure 1c; Supplementary Figure 1c; Supplementary 
Table 4). 
The MR-Egger intercept yielded no strong indication of unbalanced horizontal 
pleiotropy (β= -0.008, 95% CI: -0.043 to 0.028, p=0.691; β=0.013, 95% CI: -0.005 to 
0.030, p=0.200; and β=0.008, 95% CI: -0.009 to 0.026, p=0.375, for EGG, UK Biobank 
and GIANT respectively). The leave-one-out analyses yielded no strong indication that 
there were influential instruments (Supplementary Figure 2a; Supplementary Figure 2b; 
Supplementary Figure 2c). 
 
Effect of BMI on ADHD susceptibility 
 
Results for the effect of BMI on ADHD susceptibility are expressed as change in 
ln(odds ratio) of ADHD per each additional SD unit of BMI. The negative estimates 
indicate a negative (inverse) association; positive estimate indicates a positive 
association; a point estimate equal to zero indicates no association. 
We observed consistent evidence of a positive effect of BMI on ADHD both 
when using instruments identified in the EGG childhood BMI GWAS (β=0.324, 
95%CI: 0.198 to 0.449, p<0.001), and when using instruments identified in the GIANT 
adulthood BMI GWAS (β=0.402, 95%CI: 0.228 to 0.575, p<0.001), using the IVW 
method (Figure 2a; Figure 2b; Supplementary Table 4; Supplementary Figure 3a; 
Supplementary Figure 3b). Similar results were obtained across the other Mendelian 
randomization methods (i.e. MR-Egger, penalized weighted median and weighted 
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mode) (Supplementary Table 4; Supplementary Figure 3a; Supplementary Figure 3b). 
The MR-Egger interpret did not provide strong indication of unbalanced horizontal 
pleiotropy (β= -0.009, 95%CI: -0.051 to 0.032, p=0.664 and β= -0.005, 95%CI: -0.019 
to 0.008, p=0.438 for EGG and GIANT respectively). The leave-one-out analyses 
provided not strong indication that there were influential instruments (Supplementary 
Figure 4a; Supplementary Figure 4b). 
 
Effect of BMI on ADHD susceptibility: subgroup analyses by biological pathway  
 
To further explore the positive effect of BMI on ADHD risk suggested by our 
Mendelian randomization analyses, we performed additional sensitivity analysis in 
which the genetic instruments associated with BMI were classified as related to 
neurological or other pathways, as classified by Locke et al. (2015) 27 and used by 
Hartwig et al. (2016) 25 (Supplementary Table 3). The rationale for this analysis is 
based on the GIANT BMI GWAS results 27, which observed an important enrichment 
of neurological pathways in the genetic etiology of BMI. Then, it is possible that the 
positive association between high BMI and ADHD is led by genetic instruments 
involved in neural mechanisms that affect both BMI and ADHD independently 25. 
However, results were similar when stratifying the genetic instruments in this way. The 
IVW effect estimates were 0.377 (95%CI 0.082 to 0.673, p= 0.012) for instruments 
involved in neurological pathways, compared to 0.415 (95%CI 0.199 to 0.631, p< 
0.001) for other instruments per 1 SD increase in BMI (Figure 3b; Figure 3a; 
Supplementary Table 5). In sensitivity analyses using other Mendelian randomization 
methods, point estimates were even larger for instruments not implicated in 
neurological pathways (Figure 3b; Figure 3a; Supplementary Table 5; Supplementary 
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Figure 5b; Supplementary Figure 5a, Supplementary Figure 5b). The leave-one-out 
analysis provided no strong indication that there were influential instruments 
(Supplementary Figure 6a; Supplementary Figure 6b). 
 
DISCUSSION 
 
In the present study, we assessed causality in the association between ADHD 
and BMI using bidirectional two-sample Mendelian randomization. In the analyses with 
BMI as the exposure and ADHD as the outcome, our findings indicated a causal effect 
of higher BMI on higher ADHD risk. This result was robust to several sensitivity 
analyses exploring bias due to horizontal pleiotropy in different ways. For ADHD 
genetic liability as the exposure and BMI as the outcome, the main analysis suggested a 
causal effect of higher ADHD liability on higher BMI. However, this finding did not 
replicate across different datasets and were inconsistent across different Mendelian 
randomization estimators. 
A recent systematic review and meta-analysis of 42 studies with clinical and 
population-based samples reported an association between obesity and ADHD in 
children/adolescents and adults 12. Longitudinal studies indicate that ADHD in 
childhood is associated with higher BMI and obesity risk in adulthood, suggesting that 
ADHD precedes BMI 16-18, 40. This has led to hypotheses where ADHD triggers weight 
gain by deregulating eating behavior in several ways: (i) impulsivity would contribute 
to deficient inhibitory and delay aversion and, consequently, over-consumption 41, (ii) 
inattention would facilitate adhering to unhealthy dietary patterns 41-44, (iii) 
organizational and attention difficulties would trigger compensatory mechanisms 
leading to compulsive eating and reduced caloric expenditure 45, 46. 
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However, disentangling the direction of causal effects between conditions of 
high complexity and long latency is challenging in classical observational settings, 
including those of longitudinal design, due to issues of residual confounding and reverse 
causality. In our study, we used genetic instruments for both BMI and ADHD risk as 
proxies for exposure to these phenotypes in order to avoid issues with reverse causality 
(since germ-line genotypes precede phenotypes) and residual confounding (as genetic 
instruments tend not to be related to classical confounding factors) 47. In contrast to the 
aforementioned large meta-analysis, we did not find robust evidence for an effect of 
ADHD liability on BMI. On the other hand, we did find consistent evidence for a risk-
increasing effect of higher BMI on ADHD. 
The mechanisms potentially involved in this direction are unknown and require 
further investigation. Sleep disruption has been suggested by the most recent systematic 
review and meta-analysis as a possible contributor for this association between obesity 
and ADHD 21, 22. It is mainly based on the reports of higher frequency of  short sleep 
duration, Delayed Sleep Phase Syndrome (SDPS) 21, and late circadian rhythm among 
both individuals with obesity and with ADHD 48. According to this hypothesis, the 
discontinuation of sleep in obese individuals would lead to symptoms of ADHD 21, 22, 49, 
50.  However, evidence supporting this is too incipient and whether sleep disruption 
could be a plausible mediator of the relation between BMI and ADHD, especially 
among children, remains to be elucidated. 
 Another possible mechanism is the proinflammatory state induced by obesity 51, 
which may be a risk factor for ADHD 52 . In addition, chronic hyperglycemia may 
impair learning and memory processing 52, most commonly through affecting the frontal 
and hippocampal regions responsible for attention, cognition and motor planning. 
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Changes in these areas can lead to inattention, loss of emotions and behavioral 
inhibition, which may explain the risk of developing ADHD symptoms later 52.  
 The strengths of our study include the large sample size, the use of 
bidirectional Mendelian randomization to estimate the effect between the phenotypes in 
both directions, and the use of extensive sensitivity analyses to evaluate robustness of 
our results to horizontal pleiotropy. Some limitations of this study should also be 
considered. As any other causal inference method, Mendelian randomization relies on 
assumptions, some of which are untestable. Assumption (i) – the relevance assumption 
– states that genetic instruments should be strongly associated with the exposure of 
interest. This is the only IV assumption that is fully testable. To avoid including weak 
instruments, we only selected independent genetic instruments that were strongly 
associated with the exposure (P<5.0×10-8) in large datasets (N= 55 374 for ADHD 
instruments and N=339 226 for BMI instruments).  
Assumption (ii) – the independence assumption – refers to the fact that genetic 
instruments should not be related to confounding factors of the exposure-outcome 
association. Although genetic instruments are generally uncorrelated with classical 
confounding factors 47, assumption (ii) could be violated in case of population 
stratification where there are subgroups within the study population that have different 
frequencies of the alleles of interest and which concomitantly have different risk of 
having the outcome. To minimize population stratification bias, we restricted our 
analyses to only or predominantly European populations and used data from genome-
wide association studies that strictly accounted for population structure (Supplementary 
Table 3). 
Assumption (iii) – the exclusion restriction – states that genetic instruments 
should only affect the outcome through the exposure. This would be violated due to 
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horizontal pleiotropy, where the genetic instruments affect both the exposure and the 
outcome through independent pathways. It is impossible to empirically rule out that 
horizontal pleiotropy is driving the results. However, our results were consistent across 
a series of sensitivity analyses using different Mendelian randomization methods that 
rely on different assumptions about horizontal pleiotropy, thus strengthening causal 
inference 53. These analyses revealed a consistent effect of BMI on ADHD, but 
inconsistent results in the opposite direction. We also stratified our analysis according to 
the putative pathway regulated by the mapped genes for each genetic variant (neuronal 
or other pathways) as one would expect that, if the association between BMI and 
ADHD was explained by a common shared neurological mechanism (e.g. dopaminergic 
pathways, reward system and satiety), results would be inflated for the stratum of 
instruments assigned to neuronal pathways compared to results for the other stratum. 
However, estimates were comparable suggesting that this is unlikely to explain our 
findings. 
 The fact that we have found stronger evidence for an effect of high BMI on 
ADHD risk than for an effect in the opposite directions should be interpret with caution 
since many more genetic instruments were available to test the effect of BMI (N = 77 
variants) than the effect of ADHD liability (N = 12 variants). Therefore, we cannot 
completely rule out the possibility that we were underpowered to detect modest effects 
of ADHD liability on BMI. 
 Genetic instruments tend to reflect lifelong differences in phenotypes and, 
therefore, Mendelian randomization studies cannot identify whether there is a critical 
timing for the effect of the exposure. Therefore, even though we investigated the effect 
of BMI at different life stages (childhood and adulthood), it should be noted that BMI is 
genetically correlated across these stages. Therefore, it is possible that the effect that we 
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see for adulthood BMI might be in fact capturing an effect of BMI early in life or vice-
versa. Similarly, as maternal and offspring genotypes are correlated, the estimated 
effects of own BMI on ADHD risk could be reflecting the effect of in utero exposure to 
high maternal BMI.  
 To the best of our knowledge, this is the first Mendelian randomization study 
to probe the bidirectional relation between BMI and ADHD. We found consistent 
evidence for an effect of high BMI on ADHD risk that was replicated in independent 
samples and robust to sensitivity analyses and inconsistent evidence for an effect in the 
opposite direction contrasting with findings from conventional observational studies. 
Further studies are needed to confirm these findings and to clarify potential mechanisms 
underlying this effect. 
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Figure Legends 
 
Figure 1. Causal relationship between ADHD as exposure and BMI considering 
different datasets. Forest plots showing the effect of genetically enhanced ADHD 
(PGC) on BMI considering EGG data (n = 9 genetic instruments) (A); GIANT (n = 10 
genetic instruments) (B); and UK Biobank (n = 9 genetic instruments) (C). The results 
are shown for three effect estimates of MR tests. Forest plots show each genetic variant 
with the 95% confidence interval of the estimate of weighted mode, MR-Egger, 
penalized weighted median and inverse weighted variance results. 
 
Figure 2. Causal relationship between BMI as exposure ADHD considering different 
datasets. Forest plots showing the effect of genetically enhanced BMI (EGG) on ADHD 
(PGC) (n=16 genetic instruments) (A); and BMI (GIANT) on ADHD (PGC) (n=72 
genetic instruments) (B). The results are shown for three effect estimates of MR tests. 
Forest plots show each genetic variant with the 95% confidence interval of the estimate 
of weighted mode, MR-Egger, penalized weighted median and inverse weighted 
variance results. 
 
Figure 3. Causal relationship considering functional pathways derived from BMI 
instrumental variables as exposure. Forest plots showing the effect of genetically 
enhanced BMI (GIANT) as exposure and ADHD (PGC) for neurological pathways 
(n=42 genetic instruments) (A); and for other pathways (n=30 genetic instruments) (B). 
Forest plots show each genetic variant with the 95% confidence interval of the estimate 
of weighted mode, MR-Egger, penalized weighted median and inverse weighted 
variance results. 
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